The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 26, 2021

Filed:

Jun. 05, 2015
Applicants:

Universite DE Lille, Lille, FR;

Centre National DE LA Recherche Scientifique—cnrs—, Paris, FR;

Institut Gustave Roussy, Villejuif, FR;

Cellvax, Romainville, FR;

Universite Paris-sud, Orsay, FR;

Inventors:

Nadira Delhem, Marcq en Baroeul, FR;

Pierre Busson, Antony, FR;

Olivier Morales, Lille, FR;

Clement Barjon, Villejuif, FR;

Dhafer Mrizak, Lille, FR;

Claire Lhuillier, Le Kremlin-Bicetre, FR;

Rami Mustapha, Lille, FR;

Assignees:

Universite de Lille, Lille, FR;

Centre National de la Recherche Scientifique, Paris, FR;

Institut Gustave Roussy, Villejuif, FR;

Cellvax, Romainville, FR;

Universite Paris-Saclay, Saint Aubin, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/385 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/18 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2851 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/18 (2013.01); C07K 16/30 (2013.01); C07K 16/3092 (2013.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01);
Abstract

The invention relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.


Find Patent Forward Citations

Loading…